Continuous glucose measurement system (CGMS)
Emergence of Enzyme-based 2nd generation CGMS (1999) and limitations:
- Limitation on accuracy and persistence (calibration required twice-a-day)
- Economic burden due to short sensor replacement cycle (1 week)
- Time lag issues due to interstitial fluid-based measurements/li>
- Skin troubles due to sensor taping
2.5-generation CGMS implanted in the body
- June 2018, US FDA approved implantable CGMS Eversence from Senseonics
- FY2018 sales of Senseonics in the US: US$18.9M (about 20 billion won)
- Due to the limitations of the fluorescent material-based sensor, it needs to be replaced every 3 months.
- Still, the price per sensor is over $1,000, which is over $4,200 per year.
- Still, the problem of “time-lag”, a limitation of interstitial fluid (ISF)-based CGMS